FBIOP
HEALTHCAREFortress Biotech Inc
$14.30+0.03 (+0.21%)PRE
Live · NASDAQ · May 9, Close
AI Insight
What's Moving FBIOP Today?
No stock-specific AI insight has been generated for FBIOP yet. Check back soon — insights are generated from recent news analysis.
52-Week Range
$5.60$14.64
$14.30
Fundamentals
Market Cap$78M
P/E Ratio—
EPS$-0.86
Dividend Yield—
Dividend / Share—
ROE-1.1%
Profit Margin0.1%
Debt / Equity—
Trading
Volume10K
Avg Volume (10D)—
Shares Outstanding56.7M
FBIOP News
20 articles- Journey Medical Corporation to Announce First Quarter 2026 Financial Results on May 13, 2026Yahoo Finance·May 6, 2026
- Fortress Biotech to Participate in the H.C. Wainwright 2nd Annual Royalty Company Virtual ConferenceYahoo Finance·May 4, 2026
- Journey Medical Corporation Secures Contract with Third Major GPO for Emrosi™Yahoo Finance·Apr 21, 2026
- Fortress Biotech Reports 2025 Financial Results and Recent Corporate HighlightsYahoo Finance·Mar 31, 2026
- Fortress Biotech’s Subsidiary Cyprium Therapeutics Closes Sale of Rare Pediatric Disease Priority Review Voucher for $205 MillionYahoo Finance·Mar 30, 2026
- Journey Medical Corporation Reports Full-Year 2025 Financial Results and Recent Corporate HighlightsYahoo Finance·Mar 25, 2026
- Journey Medical Corporation to Announce Year End 2025 Financial Results on March 25, 2026Yahoo Finance·Mar 18, 2026
- Fortress Biotech’s Cyprium enters agreement to sell PRV for $205MYahoo Finance·Feb 24, 2026
- UPDATE: Fortress Biotech’s Subsidiary Cyprium Therapeutics Enters into Agreement to Sell Rare Pediatric Disease Priority Review Voucher for $205 MillionYahoo Finance·Feb 23, 2026
- Fortress Biotech’s Subsidiary Cyprium Therapeutics Enters into Agreement to Sell Rare Pediatric Disease Priority Review Voucher for $205 MillionYahoo Finance·Feb 23, 2026
- Avenue Therapeutics Enters into Exclusive Worldwide License Agreement for ATX-04 for the Treatment of Pompe DiseaseYahoo Finance·Feb 23, 2026
- Fortress Biotech, Inc. (NASDAQ:FBIO) Could Be Less Than A Year Away From ProfitabilityYahoo Finance·Jan 18, 2026
- Fortress Biotech and Cyprium Therapeutics Announce U.S. FDA Approval of ZYCUBO® (copper histidinate), the First and Only Approved Treatment for Menkes Disease in the United StatesYahoo Finance·Jan 13, 2026
- Fortress Biotech and Cyprium Therapeutics Announce FDA Acceptance of CUTX-101 NDA ResubmissionYahoo Finance·Dec 15, 2025
- Journey Medical Corporation Announces Publication of Clinical Trial Results Assessing the Impact of Emrosi™ (DFD-29) on Microbial Flora of Healthy Adults in the Journal of Drugs in DermatologyYahoo Finance·Dec 10, 2025
- Fortress Biotech (FBIO) Surpasses Q3 Earnings EstimatesYahoo Finance·Nov 14, 2025
- Fortress Biotech: Q3 Earnings SnapshotYahoo Finance·Nov 14, 2025
- Fortress Biotech Reports Third Quarter 2025 Financial Results and Recent Corporate HighlightsYahoo Finance·Nov 14, 2025
- Journey Medical Corporation Reports Third Quarter 2025 Financial Results and Recent Corporate HighlightsYahoo Finance·Nov 12, 2025
- Avenue Therapeutics Announces Acquisition of Subsidiary Baergic Bio by Axsome TherapeuticsYahoo Finance·Nov 6, 2025
All 20 articles loaded
Price Data
Open$14.28
Previous Close$14.27
Day High$14.45
Day Low$14.19
52 Week High$14.64
52 Week Low$5.60
52-Week Range
$5.60$14.64
$14.30
Fundamentals
Market Cap$78M
P/E Ratio—
EPS$-0.86
Dividend Yield—
Dividend / Share—
ROE-1.1%
Profit Margin0.1%
Debt / Equity—
Trading
Volume10K
Avg Volume (10D)—
Shares Outstanding56.7M
About Fortress Biotech Inc
Fortress Biotech, Inc., a biopharmaceutical company, develops and markets pharmaceutical and biotech products. The company is headquartered in New York, New York.
HEALTHCAREBIOTECHNOLOGY
Company Details
Security TypeStock
ExchangeNASDAQ
CurrencyUSD
Round Lot—
SICBIOTECHNOLOGY
CIK—
Composite FIGI—
Share Class FIGI—